There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new medicines and vaccines to address the root cause of disease.
Innovation
Bringing innovation to patients, better and faster
We’re harnessing the power of advanced tech, combined with our deep understanding of the science of the immune system, to develop new medicines and vaccines.
Innovating to meet patient need
We get ahead of disease together by preventing and treating it with innovation in specialty medicines and vaccines. Our R&D approach combines our scientific focus on the immune system - with the use of advanced technologies.
We are working to deliver a new generation of differentiated, needed vaccines and medicines in four core therapeutic areas where we have the strongest expertise, and where significant patient need remains: respiratory, immunology and inflammation; oncology, HIV; and infectious diseases.
Technology powers all aspects of our R&D. We use human genetics and functional genomics, along with artificial intelligence and machine learning (AI/ML), to deeply understand the patient, human biology, and disease mechanisms. This is leading to real breakthroughs for tackling a range of conditions, such as liver disease, or transforming HIV treatment and prevention.
We believe the powerful combination of science and technology holds the key to fundamentally transforming medical discovery for the better, making the R&D process more dynamic, improving success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.
Medicines and vaccines in development
58Pivotal trial starts
7
Our pipeline
As a global biopharma leader, we invest heavily in our industry-leading pipeline of potential specialty medicines and vaccines that help us to get ahead of disease together.ASSETS
58
potential vaccines and medicines
R&D
£6.6bn
R&D investment in 2025
APPROVALS
5
Major approvals in 2025
Our therapeutic areas
We prioritise research into new specialty medicines and vaccines, that can prevent and change the course of disease. We focus on four core therapeutic areas: respiratory, immunology and inflammation; oncology; HIV, and infectious diseases. These are areas where significant patient need remains and where we have the strongest expertise and greatest confidence in our ability to deliver differentiated and needed medicines and vaccines at scale.
We continue to strengthen our pipeline of medicines and vaccines, applying our growing expertise and partnerships in data and technology to increase the productivity of our R&D.
